Bleomycin resistance in Staphylococcus aureus clinical isolates | Zendy

Dimitra Gennimata | Zendy; Julian Davies | Zendy; S. Tsiftsoglour | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bleomycin resistance in Staphylococcus aureus clinical isolates

Author(s) -

Dimitra Gennimata,

Julian Davies,

S. Tsiftsoglour

Publication year - 1996

Publication title -

journal of antimicrobial chemotherapy

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/37.1.65

Subject(s) - bleomycin , staphylococcus aureus , southern blot , microbiology and biotechnology , plasmid , biology , dna , tobramycin , dot blot , bacteria , antibiotics , genetics , gentamicin , chemotherapy

Among clinical isolates of Staphylococcus aureus tested for resistance to the antibiotic bleomycin, 197 were found to be resistant; most of them were also resistant to tobramycin and contained plasmids. DNA dot-blot hybridization analysis of the bleomycin resistant isolates with an 171 bp probe derived from the plasmid pUB110 indicated that 43 strains (22%) carried pUB110-like bleomycin resistance DNA sequences. Analysis of bacterial cell lysates derived from the bleomycin resistant isolates indicated that many contained bleomycin-binding properties (BBP), that prevent DNA damage by the antibiotic. Of 13 strains that were analysed by DNA gel electrophoresis and Southern blot DNA hybridization, six were found to carry pUB110-like bleomycin resistance DNA sequences. These studies indicate that there may be more than one genetic determinant for bleomycin resistance in S. aureus whose DNA is protected.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research